


I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 4th day of March 2005.

By



(Signature of person mailing)
Madeline Deveran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: HuaZhu Ke, et al.

Examiner: Louise N. Leary

APPLICATION NO.: 09/736,051

Group Art Unit: 1654

FILING DATE: December 13, 2000

TITLE: Combination Therapy For Osteoporosis

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.


Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date: 4 MARCH 2005
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-6645



John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC9344B			SERIAL NO. 09/736,051		
									APPLICANT HuaZhu Ke, et al.					
									FILING DATE December 13, 2000			GROUP 1654		
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	5	1	6	4	3	6	8	11-17-92	Recker, et al	514	12		
	US	5	4	0	9	9	1	1	4-25-95	Tyler, et al Equivalent WO94/06750	514	91		
	US	5	7	7	3	4	7	7	6-30-98	McLean, et al	514	648		
	US	6	1	0	0	3	3	1	8-8-00	McLean, et al	514	648		
	US	6	1	1	0	9	1	8	8-29-00	Busch, et al	514	255		
	US	6	2	4	5	7	6	5	6-12-01	Busch, et al	514	252.13		
	US	6	3	0	0	2	3	2	11-27-01	Ke, et al	514	408		
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	EP	9	5	1	4	7	2	0	5-8-92	Adams, et al	A61K	37/02		
	EP	0	6	0	5	1	9	3	12-22-93	Black, et al	A61K	31/40		
	EP	0	9	0	4	7	7	4	9-16-98	Hu, et al	A61K	7/48		
	WO	9	7	2	4	3	6	9	7-10-97	Spiegel, et al	C07k	5/06		
	WO	9	7	3	1	6	7	0	9-4-97	Spiegel, et al	A61K	31/557		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Ke, et al., <u>Endocrinology</u> , "Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats" Vol. 136, pp. 2435-2441, (1995)												
		Meng, et al., <u>Journal of Bone and Mineral Research</u> , "Temporal Expression of the Anabolic Action of PTH in Cancellous Bone of Ovariectomized Rats", Vol. 11, pp. 421 – 429, (1996)												
		Neubauer et al., <u>Prostate</u> , "Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat., Vol. 23(3), pp. 245-62, (1993)												
		<u>The Merck Index</u> , 11 th Edition, pp. 1113, 1114, 1251, (1989)												
		<u>The Merck Index</u> , 12 th Edition, pp. 582, 1394, 1548, (1996)												

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC9344B		SERIAL NO. 09/736,051	
			APPLICANT HuaZhu Ke, et al.			
			FILING DATE December 13, 2000		GROUP 1654	
			Bachmann, Gloria A, Journal of National Cancer Institute Monographs, "Nonhormonal Alternatives for the Management of Early Menopause in Younger Women with Breast Cancer, Vol. 16, pp. 161-167, (1994)			
EXAMINER			DATE CONSIDERED			
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>						

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE